FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281678250> ?p ?o ?g. }

• W4281678250 endingPage "188" @default.
• W4281678250 startingPage "182" @default.
• W4281678250 abstract "Background: Broadly neutralizing monoclonal antibodies (bNAbs) suppress HIV-1 RNA and may deplete residual viral reservoirs. We evaluated the safety and pharmacokinetics (PK) of dual intravenous VRC01LS and 10-1074 in very early-treated children with HIV-1 on suppressive antiretroviral treatment (ART). Setting: Botswana. Methods: Children with HIV-1 (median age 3.1 years) on ART from <7 days old were enrolled. In phase A, 6 children received 10-1074 (30 mg/kg at day 0, 28, and 56) and 6 children received VRC01LS (30 mg/kg at day 0, 10 mg/kg at days 28 and 56) by intravenous infusion. In phase B, 6 children received the 2 bNAbs combined (with higher VRC01LS maintenance dose, 15 mg/kg) every 4 weeks for 32 weeks with PK evaluations over 8 weeks. Population PK models were developed to predict steady-state concentrations. Results: BNAb infusions were well tolerated. There were no infusion reactions nor any bNAb-related grade 3 or 4 events. The median (range) first dose Cmax and trough (day 28) combined from both phases were 1405 (876–1999) μg/mL and 133 (84–319) μg/mL for 10-1074 and 776 (559–846) μg/mL and 230 (158–294) μg/mL for VRC01LS. No large differences in bNAb clearances were observed when given in combination. The estimated VRC01LS half-life was shorter than in adults. Predicted steady-state troughs [median (90% prediction interval)] were 261 (95–565) and 266 (191–366) μg/mL for 10-1074 and VRC01LS, respectively, when given in combination. Conclusions: 10-1074 and VRC01LS were safe and well-tolerated among children receiving ART. Troughs exceeded minimal targets with every 4-week administration of 10-1074 at 30 mg/kg and VRC01LS at 15 mg/kg." @default.
• W4281678250 created "2022-06-13" @default.
• W4281678250 creator A5002215161 @default.
• W4281678250 creator A5010906104 @default.
• W4281678250 creator A5016846699 @default.
• W4281678250 creator A5019085141 @default.
• W4281678250 creator A5019383174 @default.
• W4281678250 creator A5020405624 @default.
• W4281678250 creator A5024029270 @default.
• W4281678250 creator A5025789964 @default.
• W4281678250 creator A5030501259 @default.
• W4281678250 creator A5032863083 @default.
• W4281678250 creator A5034536696 @default.
• W4281678250 creator A5037205982 @default.
• W4281678250 creator A5040076878 @default.
• W4281678250 creator A5056158090 @default.
• W4281678250 creator A5057590991 @default.
• W4281678250 creator A5058390834 @default.
• W4281678250 creator A5058715015 @default.
• W4281678250 creator A5065275718 @default.
• W4281678250 creator A5067136189 @default.
• W4281678250 creator A5071037404 @default.
• W4281678250 creator A5077967172 @default.
• W4281678250 creator A5089019812 @default.
• W4281678250 creator A5089495152 @default.
• W4281678250 creator A5089498228 @default.
• W4281678250 creator A5089772409 @default.
• W4281678250 date "2022-10-01" @default.
• W4281678250 modified "2023-09-29" @default.
• W4281678250 title "Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children" @default.
• W4281678250 cites W1555185942 @default.
• W4281678250 cites W2038110764 @default.
• W4281678250 cites W2159515958 @default.
• W4281678250 cites W2200798239 @default.
• W4281678250 cites W2346116821 @default.
• W4281678250 cites W2347047438 @default.
• W4281678250 cites W2557191642 @default.
• W4281678250 cites W2559785427 @default.
• W4281678250 cites W2572760626 @default.
• W4281678250 cites W2785308733 @default.
• W4281678250 cites W2890205877 @default.
• W4281678250 cites W2968415893 @default.
• W4281678250 cites W2984342233 @default.
• W4281678250 cites W3000416417 @default.
• W4281678250 cites W3003228485 @default.
• W4281678250 cites W3082871876 @default.
• W4281678250 cites W3138945586 @default.
• W4281678250 cites W3157202113 @default.
• W4281678250 doi "https://doi.org/10.1097/qai.0000000000003033" @default.
• W4281678250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36094485" @default.
• W4281678250 hasPublicationYear "2022" @default.
• W4281678250 type Work @default.
• W4281678250 citedByCount "7" @default.
• W4281678250 countsByYear W42816782502022 @default.
• W4281678250 countsByYear W42816782502023 @default.
• W4281678250 crossrefType "journal-article" @default.
• W4281678250 hasAuthorship W4281678250A5002215161 @default.
• W4281678250 hasAuthorship W4281678250A5010906104 @default.
• W4281678250 hasAuthorship W4281678250A5016846699 @default.
• W4281678250 hasAuthorship W4281678250A5019085141 @default.
• W4281678250 hasAuthorship W4281678250A5019383174 @default.
• W4281678250 hasAuthorship W4281678250A5020405624 @default.
• W4281678250 hasAuthorship W4281678250A5024029270 @default.
• W4281678250 hasAuthorship W4281678250A5025789964 @default.
• W4281678250 hasAuthorship W4281678250A5030501259 @default.
• W4281678250 hasAuthorship W4281678250A5032863083 @default.
• W4281678250 hasAuthorship W4281678250A5034536696 @default.
• W4281678250 hasAuthorship W4281678250A5037205982 @default.
• W4281678250 hasAuthorship W4281678250A5040076878 @default.
• W4281678250 hasAuthorship W4281678250A5056158090 @default.
• W4281678250 hasAuthorship W4281678250A5057590991 @default.
• W4281678250 hasAuthorship W4281678250A5058390834 @default.
• W4281678250 hasAuthorship W4281678250A5058715015 @default.
• W4281678250 hasAuthorship W4281678250A5065275718 @default.
• W4281678250 hasAuthorship W4281678250A5067136189 @default.
• W4281678250 hasAuthorship W4281678250A5071037404 @default.
• W4281678250 hasAuthorship W4281678250A5077967172 @default.
• W4281678250 hasAuthorship W4281678250A5089019812 @default.
• W4281678250 hasAuthorship W4281678250A5089495152 @default.
• W4281678250 hasAuthorship W4281678250A5089498228 @default.
• W4281678250 hasAuthorship W4281678250A5089772409 @default.
• W4281678250 hasConcept C112705442 @default.
• W4281678250 hasConcept C126322002 @default.
• W4281678250 hasConcept C203014093 @default.
• W4281678250 hasConcept C22979827 @default.
• W4281678250 hasConcept C2908647359 @default.
• W4281678250 hasConcept C3013748606 @default.
• W4281678250 hasConcept C44249647 @default.
• W4281678250 hasConcept C71924100 @default.
• W4281678250 hasConcept C90924648 @default.
• W4281678250 hasConcept C99454951 @default.
• W4281678250 hasConceptScore W4281678250C112705442 @default.
• W4281678250 hasConceptScore W4281678250C126322002 @default.
• W4281678250 hasConceptScore W4281678250C203014093 @default.
• W4281678250 hasConceptScore W4281678250C22979827 @default.
• W4281678250 hasConceptScore W4281678250C2908647359 @default.
• W4281678250 hasConceptScore W4281678250C3013748606 @default.
• W4281678250 hasConceptScore W4281678250C44249647 @default.

• next